Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.
about
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.Systemic glucocorticoid use and early-onset basal cell carcinomaMalignancy validation in a United States registry of rheumatoid arthritis patients.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis.The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics RegisterConcordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsTofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeMalignancy rates in patients with rheumatoid arthritis treated with tocilizumab.Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate.Examining the use of ICD-9 diagnosis codes for primary immune deficiency diseases in New York State.The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980-2007 in relation to a Comparator Cohort: A Population-Based StudyAnti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomesSafety of biologic therapy in rheumatoid arthritis.Overview of safety of non-biologic and biologic DMARDs.Infectious and malignant complications of TNF inhibitor therapy in IBD.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Optimal management of skin cancer in immunosuppressed patients.Safety issues and concerns of new immunomodulators in rheumatology.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study.Cutaneous squamous cell carcinoma: an epidemiological review.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Methotrexate increases the risk of melanoma: or does it?Biologics in dermatology: adverse effects.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.[Phototherapy in the era of biologicals].Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
P2860
Q31041008-25520BE9-FB61-4590-A3FF-83F1EC4E640CQ33992197-DC7F927F-082D-48E8-AB9D-4413091185FFQ34287960-7138B54B-870E-4367-B52B-33C0CBF034C5Q34520662-6BAD8DD6-43AC-497E-BF43-7ACBC9058E8FQ35026464-595CBF57-D37F-449D-9C44-2B2352AD179AQ35850017-F2098479-CF16-442B-BB20-93B3BAB80F95Q36020193-B6B5D7A3-DD04-465B-9BDE-D28B5F308A8AQ36158922-5377F506-8616-4E7D-B303-5A7FAFA620E1Q36859619-84B38074-DCDA-439A-B06C-ECB8321C3AE4Q36919914-067EEE47-8765-4729-B9EE-31B2D8A20412Q36923376-3E7D4B6F-C2B0-426C-81E6-3DF190062069Q36949421-EC2BA15F-AD7F-4747-924D-C8FE8575A41AQ37196596-A6A0309B-07C4-4354-87F0-2FB6C91F8CC4Q37218755-53BA71C7-6ECC-4C8B-81EB-682E7B05A6B0Q37354812-16DB264C-CED2-4B2E-BA90-0C8FA7DA3B17Q37944433-2B9FD75E-FA75-4561-896C-97018B33505CQ38065768-DF7327B1-ADC1-4B2F-9328-7C821B193FE9Q38138343-5AA74BF3-3A31-4927-8F95-343A5254B308Q38176745-D468A695-E113-4DB3-8D06-6D7ABB373AF9Q38228585-ABD6C5FE-9528-4757-83CB-7E79F5F19350Q38292111-3CE1D9F3-8DB2-4070-90AD-783CF717C217Q38668352-7711B893-B72B-4AC9-A477-C92D865E0BADQ38827889-5C47E508-22C6-4E74-8B1E-AD63C5756678Q39137571-962FE47B-C2C8-4AFF-9DEB-9E5734E9B6A3Q39140315-D38D8B46-6F26-4B73-82F1-2AB397F80E3CQ39309064-F5A02519-0D0E-4A41-92DE-4022F78AE83BQ40172889-60C735EF-3869-4ABD-95EB-F4CBBC04A74FQ41120913-B75AA97B-D67B-48C9-97B5-F4BDF9AE6B5FQ41176187-CD7111E2-CFF0-44D0-8A86-F78DA16B3ACFQ41650730-2B710BCF-E71C-40D4-9B28-885972B28FCFQ43872006-37067958-A607-4AE2-AB8E-1D30DB962AA4Q58802123-D7796CBC-DB06-42DE-B9A9-07877E5C25F9
P2860
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@en
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@nl
type
label
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@en
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@nl
prefLabel
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@en
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@nl
P2093
P2860
P356
P1433
P1476
Risk of non-melanoma skin canc ...... ans with rheumatoid arthritis.
@en
P2093
Angelique L Zeringue
Jay R McDonald
Liron Caplan
Prabha Ranganathan
Seth A Eisen
Wassila Amari
P2860
P304
P356
10.1093/RHEUMATOLOGY/KER113
P577
2011-03-16T00:00:00Z